Alexandra (Sandra) Glucksmann

Sandra Glucksmann joined Adjuvant as an Advisory Partner and Investment Committee member in 2023. She currently serves as Chief Executive Officer of Sensorium Therapeutics.

A veteran biopharma executive and experienced scientist with over 30 years in biotech, Sandra most recently served as founding CEO and President of Cedilla Therapeutics and previously was founding Chief Operating Officer of Editas Medicine, Inc. She serves on the boards of directors of gene therapy company REGENXBIO and and genetic modifiers company Scenic Biotech. Sandra holds a Ph.D. with honors in molecular genetics and cell biology from the University of Chicago.